E-cigarette Sales Surge by Almost 50%: CDC Data

Jun.25.2023
E-cigarette Sales Surge by Almost 50%: CDC Data
CDC data shows e-cigarette sales increased nearly 50% in three years, led by non-tobacco flavors. Sales of disposable e-cigarettes surpassed pod systems.

According to CBS News, data released by the U.S. Centers for Disease Control and Prevention (CDC) shows that e-cigarette sales have grown by nearly 50% over the past three years, increasing from 15.5 million in January 2020 to 22.7 million in December 2022.


These data come from an analysis by the Centers for Disease Control and Prevention of data from market research companies. The analysis was published in the agency's "Morbidity and Mortality Weekly Report.


One-time-use sales surpass replaceable magazine sales.


Fatma Romeh, the Chief Market Analyst at CDC, stated in a declaration that...


The significant increase in e-cigarette sales from 2020 to 2022 is primarily driven by the growth of non-tobacco flavored e-cigarettes, such as the dominance of mint flavor in the prefilled pod market and the leading position of fruit and candy flavors in the disposable e-cigarette market.


According to the national youth tobacco survey data released in 2022, more than 80% of middle and high school students use e-cigarettes with fruit or mint flavors, as pointed out by Romei.


According to data, even though disposable e-cigarettes accounted for less than a quarter of total sales in January 2020, by March 2022 disposable e-cigarette sales surpassed pod system sales.


From January 2020 to December 2022, the unit share of pod systems decreased from 75.2% of total sales to 48.0%, while the unit share of disposable e-cigarettes increased from 24.7% to 51.8%.


Sales of e-cigarettes | Image source: Centers for Disease Control and Prevention in the United States


Sales volume of pod systems | Image source: Centers for Disease Control and Prevention in the United States.


Sales of disposable e-cigarettes | Image source: Centers for Disease Control and Prevention in the United States.


The total number of e-cigarette brands in the market has increased by 46.2%.


According to data, the number of e-cigarette brands in the United States market is continually increasing. During the CDC study, the total number of e-cigarette brands in the US market increased by 46.2%, from 184 to 269.


Deirdre Lawrence Kittner, the Director of Smoking and Health Office at the CDC, stated in a release:


The sharp rise in e-cigarette use among teenagers in 2017 and 2018, fueled largely by JUUL, highlights the rapid evolution of sales and use patterns in the e-cigarette industry.


The overall sales growth of e-cigarettes has slowed down.


According to data, total sales increased by 67.2% from January 2020 to May 2022, rising from 15.5 million units per period to 25.9 million units. However, from May 2022 to December 2022, total sales decreased by 12.3%.


Even though overall monthly sales have been decreasing since May 2022, sales are still millions higher compared to early 2020. The CDC attributes the recent decline to several factors, including the efforts of health departments to regulate the sales of nicotine products.


At the national level, the FDA has taken multiple measures this year in an effort to curb unauthorized sales of e-cigarettes.


Director of the Center for Tobacco Products (CTP) at the FDA, Brian King, stated in a declaration that:


All participants in the supply chain, including retailers, have a responsibility to prevent illegal e-cigarettes from being placed on the market.


A previous CDC study report analyzed that the comprehensive flavor ban in Massachusetts resulted in a sharp decline of 94% in the sales of flavored e-cigarettes in the state.


It is worth noting that more and more state and local governments in the United States are also attempting to impose restrictions on the sale of flavored e-cigarettes.


As of December 31, 2022, seven states (California, Maryland, Massachusetts, New Jersey, New York, Rhode Island, and Utah) and 378 jurisdictions (including counties, cities, towns, and villages) have implemented some form of restriction on flavored electronic products.


The CDC acknowledged that other factors may also contribute to the sales slowdown, including the increase in high-dose or high-volume disposable e-cigarettes purchased at one time, resulting in more or stronger doses each time.


Moreover, this data is limited to the sales performance of traditional brick-and-mortar retailers. This suggests that some sales may not have actually declined, but instead shifted elsewhere, such as online orders or specialized e-cigarette stores not included in the company's sales data.


References:


Health officials have raised concerns about the surge in e-cigarette sales, which have coincided with a rise in calls to poison control centers.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
A 12-week European Commission consultation on revising the Tobacco Products Directive and Tobacco Advertising Directive is due to close on Aug. 14, 2026. The Commission has identified e-cigarette flavours, disposable vapes, tobacco heating devices, nicotine pouches, nicotine-free e-cigarettes, packaging and digital marketing among areas for possible new EU rules. National regulations already vary significantly across the bloc, a fragmentation the Commission says creates internal-market barriers and distorts competition. No formal revised TPD/TAD legislative text has yet been published, with the Commission currently indicating December 2026 for the legislative initiative.
Aug.14
Research | Swedish Study Finds Oral Lesions in 79% of Examined Nicotine Pouch Users, With Distinct Tissue Responses
Research | Swedish Study Finds Oral Lesions in 79% of Examined Nicotine Pouch Users, With Distinct Tissue Responses
A new Swedish study found oral mucosal lesions in 79% of examined nicotine pouch users and 89% of tobacco-derived snus users, with different tissue-response patterns between the two categories. For manufacturers and regulators, the findings shift attention toward product formulation, flavouring, pouch materials and local oral exposure, not only whether a product contains tobacco. The study found no higher prevalence of caries or periodontal disease, but it could not establish causality, long-term outcomes or differences between individual products or designs.
Special Report
Jul.27
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
French Vape Market Under Pressure as Europe’s First Listed Vape Company Kumulus Vape Reports 7.8% H1 Revenue Decline, Retail Sales Rise 41.5%
French Vape Market Under Pressure as Europe’s First Listed Vape Company Kumulus Vape Reports 7.8% H1 Revenue Decline, Retail Sales Rise 41.5%
Kumulus Vape, Europe’s first publicly listed vape company, reported a 7.8% year-on-year decline in first-half 2026 revenue. Amid changing conditions in France’s vape market, the company said channel diversification helped offset pressure, with physical store sales increasing 41.5% year on year. Listed on Euronext Access Paris in 2019 and later transferred to Euronext Growth Paris, Kumulus Vape is viewed as a representative company of Europe’s vape sector. Its performance highlights the industry’s shift from rapid expansion toward more operationally focused growth.
Jul.27
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
A new expert paper in JAMA urges U.S. clinicians to include nicotine e-cigarettes in smoking-cessation discussions, citing higher quit rates than nicotine replacement therapy. It also stresses that products must deliver enough nicotine to replace cigarettes, dual use should be brief, and complete switching is the goal. 2Firsts argues the recommendations matter beyond clinics: public-health professionals should reassess relative risk, regulators should preserve sufficient product appeal for adult smokers, and manufacturers should focus on helping users quit cigarettes more sustainably.
SCIENCE
Aug.03 by 2Firsts Perspectives